AHA Conference 2024 - Safety and efficacy outcomes of muvalaplin (Eli Lilly and Company) in adults with elevated lipoprotein(a) at high risk for cardiovascular events.

Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from KRAKEN (NCT05563246).

KRAKEN is a phase 2, randomized, placebo-controlled trial investigating the use of an oral, daily dose of LY3473329 in adults aged 40 or over with elevated lipoprotein(a) at high risk for cardiovascular events. 233 patients were enrolled in the trial and were followed up at baseline and week 12. The primary outcome measure was the percent change from baseline in lipoprotein(a).

Interview Questions:
1.    What is the importance behind the KRAKEN trial?
2.    Could you tell us about the mechanism of action behind muvalaplin?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    Were there any surprising or unexpected results?
6.    What further research is needed in this area, and what are the next steps?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.